After sifting through would-be licensors, Depomed Inc. is entering a $50 million deal with Esprit Pharma Inc. to market and distribute Proquin XR, the extended-release form of ciprofloxacin hydrochloride for the treatment of uncomplicated urinary tract infections. (BioWorld Today) Read More
